RxDoctor Payments Data

Adam Shook

Medical · Danbury, CTNPI 1346643806

Payments from drug & device makers

$2,763in general payments, 2019–2025

Across 116 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$535
  • Gilead$490
  • Organogenesis Inc.$453
  • Smith+Nephew$384
  • Reddress USA, Inc.$236
  • Reprise Biomedical, Inc.$96
  • plus $568 from 18 others

What the payments were for

  • Food & beverage$2,763100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,763 in reported general payments places this provider in the 85th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$82,994
Medicare patients
340
Services billed
1,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala219$916,762
OdefseyEmtricitab/Rilpiviri/Tenof Ala62$258,196
DovatoDolutegravir Sodium/Lamivudine41$139,382
JulucaDolutegravir/Rilpivirine33$119,824
TivicayDolutegravir Sodium20$69,931
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$47,430
DescovyEmtricitabine/Tenofov Alafenam19$43,875
TriumeqAbacavir/Dolutegravir/Lamivudi12$39,772
PrezcobixDarunavir/Cobicistat13$28,297
Etravirine13$8,718
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$4,511
Methenamine Hippurate27$3,171
Gentamicin Sulfate31$1,188
Doxycycline Monohydrate18$966
Cefadroxil59$856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$490$1,008,066250 claims
Viiv Healthcare CompanyDovato, Juluca, Tivicay, Triumeq$535$368,909106 claims
Johnson & JohnsonPrezcobix$50$28,29713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 592 medical providers in Connecticut.

Other medical in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →